IRIDEX publishes glaucoma study: what USD 12.6 million revenue means for IRIDEX stock

Published on 10/16/2026 at 00:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A 24-month study covered 84 eyes and reached 14.05 mmHg pressure. USD 0.6 million in savings now frames IRIDEX stock.

Clinical evidence and operating costs

IRIDEX published a two-year glaucoma study on October 12, 2026, covering 84 eyes.
Second-quarter 2026 revenue reached USD 12.6 million against a USD 14.13 million forecast.
The October 5, 2026 facility move targets USD 0.6 million in annualized savings.

IRIX, US4626841013, Illustration mit AI erstellt.

IRIDEX Corporation (ISIN US4626841013) announced on October 12, 2026 that a two-year study of its MicroPulse treatment covered 84 eyes and reduced mean intraocular pressure to 14.05 mmHg from 22.32 mmHg at baseline, according to Yahoo Finance. The clinical evidence gives the small medical-device company a concrete operating narrative after a weak second quarter.

What does the study show?

The retrospective study followed patients with primary open-angle or primary angle-closure glaucoma for 24 months. Mean use of topical pressure-lowering medication fell from 2.96 to 2.38, while treatment success reached 86 percent in primary open-angle glaucoma and 81 percent in primary angle-closure glaucoma, Yahoo Finance reported on October 12, 2026. The study therefore supports broader use of the technology, but it remains clinical evidence rather than a sales forecast.

Three events shape the story

On August 18, 2026, IRIDEX reported second-quarter revenue of USD 12.6 million against a USD 14.13 million forecast and adjusted? no, GAAP earnings per share of minus USD 0.07 against a minus USD 0.02 estimate, according to Investing.com. On October 5, 2026, the company completed its move from Mountain View to San Jose and said it expected USD 0.6 million in annualized cost savings, according to GlobeNewswire. The October 12 study then added an operating proof point, with 84 eyes and an 81 percent success rate in angle-closure glaucoma.

Next date for financial results

IRIDEX is scheduled to report its next financial results on November 17, 2026, according to the earnings calendar displayed by Investing.com. That release should show whether the cost reduction plan and glaucoma demand are translating into revenue performance.

Costs and commercial proof

IRIDEX develops laser systems, delivery devices and consumable instruments for ophthalmology. Its second-quarter revenue of USD 12.6 million was below the USD 14.13 million forecast, while the facility move is expected to reduce annual costs by USD 0.6 million. The next report will connect the study's clinical results with sales execution.